Novacyt (LON:NCYT) Shares Down 4.8% – What’s Next?

Novacyt S.A. (LON:NCYT) shares traded down 4.8% on Tuesday . The company traded as low as GBX 51.26 ($0.64) and last traded at GBX 51.70 ($0.64). 121,140 shares changed hands during trading, a decline of 72% from the average session volume of 429,463 shares. The stock had previously closed at GBX 54.30 ($0.68).

Novacyt Stock Down 4.8 %

The firm’s fifty day moving average is GBX 52.16 and its two-hundred day moving average is GBX 58.72. The firm has a market cap of £36.52 million, a price-to-earnings ratio of -99.42 and a beta of -1.86. The company has a debt-to-equity ratio of 18.67, a current ratio of 4.04 and a quick ratio of 4.46.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.